These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 35932380)

  • 21. Subtyping of male breast cancer by PAM50 and immunohistochemistry: a pilot study of a consecutive Danish cohort.
    Christensen LG; Lautrup MD; Lyng MB; Möller S; Jylling AMB
    APMIS; 2020 Sep; 128(9):523-530. PubMed ID: 32579768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance.
    Abadie J; Nguyen F; Loussouarn D; Peña L; Gama A; Rieder N; Belousov A; Bemelmans I; Jaillardon L; Ibisch C; Campone M
    Breast Cancer Res Treat; 2018 Jan; 167(2):459-468. PubMed ID: 29063312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes.
    Caan BJ; Sweeney C; Habel LA; Kwan ML; Kroenke CH; Weltzien EK; Quesenberry CP; Castillo A; Factor RE; Kushi LH; Bernard PS
    Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):725-34. PubMed ID: 24521998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer.
    Dhawan D; Hahn NM; Ramos-Vara JA; Knapp DW
    PLoS Genet; 2018 Aug; 14(8):e1007571. PubMed ID: 30089113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry.
    Sassi F; Benazzi C; Castellani G; Sarli G
    BMC Vet Res; 2010 Jan; 6():5. PubMed ID: 20109214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer.
    Seksenyan A; Kadavallore A; Walts AE; de la Torre B; Berel D; Strom SP; Aliahmad P; Funari VA; Kaye J
    BMC Cancer; 2015 Jan; 15():22. PubMed ID: 25632947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
    Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
    Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative expression pathway analysis of human and canine mammary tumors.
    Uva P; Aurisicchio L; Watters J; Loboda A; Kulkarni A; Castle J; Palombo F; Viti V; Mesiti G; Zappulli V; Marconato L; Abramo F; Ciliberto G; Lahm A; La Monica N; de Rinaldis E
    BMC Genomics; 2009 Mar; 10():135. PubMed ID: 19327144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
    Ren X; Song Y; Zhang Y; Wu H; Chen L; Pang J; Zhou L; Shen S; Liang Z
    BMC Cancer; 2022 May; 22(1):548. PubMed ID: 35568835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphogenic and tumorigenic potentials of the mammary growth hormone/growth hormone receptor system.
    van Garderen E; Schalken JA
    Mol Cell Endocrinol; 2002 Nov; 197(1-2):153-65. PubMed ID: 12431808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study.
    Wang L; Li Q; Aushev VN; Neugut AI; Santella RM; Teitelbaum S; Chen J
    Breast Cancer; 2021 Nov; 28(6):1235-1242. PubMed ID: 34003448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus at
    Madsen MJ; Knight S; Sweeney C; Factor R; Salama M; Stijleman IJ; Rajamanickam V; Welm BE; Arunachalam S; Jones B; Rachamadugu R; Rowe K; Cessna MH; Thomas A; Kushi LH; Caan BJ; Bernard PS; Camp NJ
    Cancer Epidemiol Biomarkers Prev; 2018 Jun; 27(6):644-652. PubMed ID: 29650789
    [No Abstract]   [Full Text] [Related]  

  • 35. Micro RNA differential expression profile in canine mammary gland tumor by next generation sequencing.
    Chen HW; Lai YC; Rahman MM; Husna AA; Hasan MN; Miura N
    Gene; 2022 Apr; 818():146237. PubMed ID: 35077831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs).
    Kjällquist U; Erlandsson R; Tobin NP; Alkodsi A; Ullah I; Stålhammar G; Karlsson E; Hatschek T; Hartman J; Linnarsson S; Bergh J
    BMC Cancer; 2018 Feb; 18(1):174. PubMed ID: 29433456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer.
    Treekitkarnmongkol W; Katayama H; Kai K; Sasai K; Jones JC; Wang J; Shen L; Sahin AA; Gagea M; Ueno NT; Creighton CJ; Sen S
    Carcinogenesis; 2016 Dec; 37(12):1180-1189. PubMed ID: 27624071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Research progress of good markers for canine mammary carcinoma.
    Yang NY; Zheng HH; Yu C; Ye Y; Du CT; Xie GH
    Mol Biol Rep; 2023 Dec; 50(12):10617-10625. PubMed ID: 37943402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.
    Pfefferle AD; Agrawal YN; Koboldt DC; Kanchi KL; Herschkowitz JI; Mardis ER; Rosen JM; Perou CM
    Dis Model Mech; 2016 Jul; 9(7):749-57. PubMed ID: 27149990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.